Xavitaz

# Xavitaz ## Overview - **Classification**: Novel broad-spectrum antibiotic (Fluoroquinolone derivative) - **Mechanism**: Inhibits bacterial DNA gyrase and topoisomerase IV, leading to DNA strand breaks and bacterial cell death. ## Primary Indications 1. **Community-acquired Pneumonia (CAP)** - Treatment of susceptible bacterial infections. 2. **Complicated Urinary Tract Infections (cUTI)** - Including pyelonephritis. 3. **Acute Bacterial Skin and Skin Structure Infections (ABSSSI)** - With or without bacteremia. ## Adult Dosing ### Standard Dosing **Community-acquired Pneumonia / ABSSSI** - **Dose**: **500 mg** - **Frequency**: Once daily - **Route**: Oral or Intravenous (IV) - **Duration**: 7-14 days, depending on infection severity **Complicated Urinary Tract Infections (cUTI)** - **Dose**: **250 mg** - **Frequency**: Once daily - **Route**: Oral or Intravenous (IV) - **Duration**: 5-7 days ### Dose Adjustments - **Renal Impairment**: - CrCl 30-50 mL/min: No dose adjustment needed. - CrCl <30 mL/min or Hemodialysis: **250 mg** every **48 hours**. - **Hepatic Impairment**: No dose adjustment required for mild to moderate impairment. Use with caution in severe hepatic impairment; monitor liver function. - **Elderly Patients**: No specific dose adjustment based on age alone; consider age-related decline in renal function. ## Pediatric Dosing ### Neonates (0-28 days) - **Dose**: Not recommended due to potential for irreversible cartilage damage. - **Special Notes**: Use only if no alternative therapy is available and benefit outweighs risk. Limited safety data. ### Infants (1-12 months) - **Dose**: **5 mg/kg** - **Frequency**: Once daily - **Maximum**: **100 mg/dose** - **Special Notes**: Use only for serious infections where other antibiotics are not suitable due to risk of arthropathy. ### Children (1-12 years) - **Dose**: **7.5 mg/kg** - **Frequency**: Once daily - **Maximum**: **250 mg/dose**, up to a maximum of **500 mg/day** - **Special Notes**: Reserved for specific severe infections (e.g., multi-drug resistant) due to musculoskeletal adverse effects. ### Adolescents (13-18 years) - **Dose**: Follow adult dosing recommendations. - **Maximum**: **500 mg/day** - **Special Notes**: Consider growth plate closure status and weigh risks/benefits. ## Safety Information ### Contraindications - **Absolute**: Hypersensitivity to Xavitaz, other fluoroquinolones, or excipients. - **Absolute**: History of QTc prolongation or Torsades de Pointes. - **Absolute**: Co-administration with Class IA or Class III antiarrhythmics. ### Common Adverse Effects - **Very Common (>10%)**: Nausea, Diarrhea, Headache. - **Common (1-10%)**: Dizziness, Insomnia, Vomiting, Abdominal pain, Rash. - **Serious but Rare**: Tendon rupture, QTc prolongation, _Clostridioides difficile_ infection, Peripheral neuropathy, Seizures. ### Key Drug Interactions - **Antacids/Polyvalent Cations (e.g., Iron, Zinc, Magnesium, Aluminum, Sucralfate)**: Significantly decreased Xavitaz absorption. Administer Xavitaz at least **2 hours before** or **6 hours after** these agents. - **Warfarin**: May enhance anticoagulant effects, increasing bleeding risk. Monitor INR closely. - **Class IA/III Antiarrhythmics (e.g., Quinidine, Amiodarone, Sotalol)**: Increased risk of QTc prolongation and arrhythmias. Concomitant use is contraindicated. - **Corticosteroids**: Increased risk of tendon rupture, especially in elderly patients. ## Monitoring & Follow-up - **Before Treatment**: Baseline renal function (CrCl), Electrolytes (K+, Mg2+), ECG (if cardiac risk factors present). - **During Treatment**: Monitor for clinical response, resolution of infection symptoms, and adverse effects. Renal function for prolonged therapy. - **Clinical Signs**: New onset tendon pain/swelling, muscle weakness, severe or persistent diarrhea, chest pain, palpitations, or signs of neuropathy (numbness, tingling). ## Clinical Pearls - 💡 **Tip 1**: Administer Xavitaz orally separate from dairy products and calcium-fortified juices, which can reduce absorption. - 💡 **Tip 2**: Counsel patients immediately report any tendon pain or swelling; discontinue Xavitaz if suspected. - 💡 **Tip 3**: Emphasize importance of hydration to prevent crystalluria, although rare with Xavitaz. - 💡 **Tip 4**: Avoid excessive sun exposure during treatment due to photosensitivity risk. > **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.